

PRESS RELEASE

The French Prime minister Jean-Marc Ayrault, accompanied by Fleur Pellerin, deputy to the French minister of industrial renewal visited on Friday, November 9, 2012 Cellectis' industrial platform

Paris, France, November 9th, 2012 – <u>Cellectis</u> (Alternext: ALCLS), the <u>genome-engineering</u> specialist, received on Friday, November 9, 2012 the Prime Minister Jean-Marc Ayrault, accompanied by Fleur Pellerin, deputy to the French minister of industrial renewal in charge of small and medium-sized businesses, innovation, and the digital economy.



Jean-Marc Ayrault, Fleur Pellerin and André Choulika, CEO of Cellectis Group¹

During his visit, the Prime Minister has expressed a strong interest in the Group's business model and extensively interacted with the present employees.

During his discussions with André Choulika, CEO of Cellectis Group, Mr. Ayrault reaffirmed its commitment to the revitalization of French industry arguing the importance of companies with high potential for innovation in this process.

André Choulika has, on this occasion, thanked the Prime Minister for his encouragement, before recalling the massive industrial revolution taking place in the world, driven by the biotechnology industry.

Taking advantage of his meeting with the Prime Minister, André Choulika expressed his belief in the inevitability of a trend reversal mode of relationship between large companies and innovative SMEs. "Breakthrough innovations in the industry of life sciences are mostly today the work of young technology companies that expose themselves to the inherent risks in innovation."

About Cellectis

Founded in France in 1999, the Cellectis Group is based on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Co-created

Press release I Cellectis



by André Choulika, its Chief Executive Officer, Cellectis is today one of the world leading companies in the field of genome engineering. The Group has a workforce of 230 employees working on 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in the United States. Cellectis achieved revenues of €16M in 2011 and has since its inception has signed more than 80 industrial agreements with pharmaceutical, agrochemical, and biotechnology companies. AFM, DuPont, BASF, Bayer, Total, Limagrain, and Novo Nordisk are some of the Group's clients and partners.

Since 2007, Cellectis has been listed on NYSE-Euronext Alternext market (code: ALCLS) in Paris. For more information, visit our website: <u>www.cellectis.com</u>

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Cellectis

Philippe Valachs Company Secretary Tel: +33 (0)1 81 69 16 00 media@cellectis.com